Virtus Investment Advisers LLC Sells 9,611 Shares of REGENXBIO Inc. $RGNX

Virtus Investment Advisers LLC lessened its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 51.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,219 shares of the biotechnology company’s stock after selling 9,611 shares during the quarter. Virtus Investment Advisers LLC’s holdings in REGENXBIO were worth $76,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in RGNX. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in REGENXBIO by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 2,326 shares in the last quarter. Brooklyn Investment Group raised its position in REGENXBIO by 163.7% during the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in REGENXBIO by 754.1% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 5,000 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of REGENXBIO by 26.5% in the 2nd quarter. Intech Investment Management LLC now owns 27,100 shares of the biotechnology company’s stock worth $222,000 after buying an additional 5,682 shares during the period. Finally, American Century Companies Inc. grew its position in shares of REGENXBIO by 6.9% during the 1st quarter. American Century Companies Inc. now owns 101,579 shares of the biotechnology company’s stock worth $726,000 after buying an additional 6,553 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Stock Up 0.6%

RGNX opened at $13.34 on Monday. The company has a market cap of $675.27 million, a price-to-earnings ratio of -3.84 and a beta of 1.14. The firm’s fifty day simple moving average is $11.55 and its two-hundred day simple moving average is $9.84. REGENXBIO Inc. has a 52-week low of $5.03 and a 52-week high of $13.93.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The company had revenue of $29.73 million during the quarter, compared to analyst estimates of $24.41 million. On average, research analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current year.

Insider Transactions at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. This trade represents a 8.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 36,169 shares of company stock valued at $416,598 over the last three months. Corporate insiders own 12.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on RGNX shares. Royal Bank Of Canada upped their price objective on shares of REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a research note on Tuesday, October 7th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, November 20th. Wall Street Zen upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Barclays decreased their price objective on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.